Research programme: thrombin receptor inhibitors - Millennium/Ortho-McNeil

Drug Profile

Research programme: thrombin receptor inhibitors - Millennium/Ortho-McNeil

Alternative Names: Thrombin receptor inhibitors research programme - Millennium/Ortho-McNeil

Latest Information Update: 26 Aug 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Millennium Pharmaceuticals; Ortho-McNeil
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Reperfusion injury; Stroke

Most Recent Events

  • 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
  • 28 Feb 2002 Discontinued - Preclinical for Ischaemic heart disorders in USA (unspecified route)
  • 28 Feb 2002 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top